Neurology
Inflammatory Myopathies
0
Pipeline Programs↗
1
Active Trials↗
0
Companies Involved↗
Inflammatory Myopathies is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
2
clinical trials
Not yet recruiting1 · 50%
Completed1 · 50%
Clinical Trials
Trial Activity
TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)
Not yet recruiting·—·Phase 2/3·NCT07355257·30 enrolled
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00001261·120 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)